Previous 10 | Next 10 |
3 Penny Stocks to Add to Your Watchlist This Week Are penny stocks worth it right now? That’s a tough question to answer, as there are pros and cons to consider. On the one hand, penny stocks are often seen as a high-risk investment, so there’s definitely potential for...
Athersys, Inc. ( NASDAQ: ATHX ) shares rallied Friday after the regenerative medicine company announced an amended Securities Purchase Agreement in relation to a previously closed stock and warrants offering, which, according to its management, offered more financial flexibili...
Best Penny Stocks To Buy We’ve discussed ways to find the best penny stocks to buy. It all boils down to your trading style and stock market strategy. Essentially, how you trade will determine the types of stocks you look at. If you’re swing trading, chances are that o...
Athersys ( NASDAQ: ATHX ) has extended the exercise period of the warrants that were issued as part of a registered direct offering that closed on August 17, 2022. Pursuant to the amendment, the exercise period of the initial warrants has been extended from five years to s...
Provides Additional Financial Flexibility in Exchange for New Warrants with a $6.385 Exercise Price Company to hold a business update conference call the week of October 3 rd Athersys, Inc. (NASDAQ: ATHX) , a regenerative medicine company developing MultiStem...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Anti-aging stocks have not proven immune to poor market conditions that have plagued the broader biotech industry. The biotech industry remains hampered by the same bleak economic conditions as those affecting growth comp...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: g0d4ather / Shutterstock.com We’re starting off another week with a deep dive into the short squeeze stocks to watch! Short squeeze stocks have been popular with traders in recent months as they searc...
Athersys ( NASDAQ: ATHX ) announced Thursday it plans to execute a 1-for-25 reverse stock split of common shares, effective market close on Aug 26, 2022. That means every 25 shares of Athersys common stock issued and outstanding will be combined into 1 share. The stock...
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25 after the close of tr...
Athersys, Inc. (Nasdaq: ATHX) today announced the closing of its previously announced registered direct offering with a single healthcare-focused U.S. institutional investor for the purchase of 48,000,000 shares of the Company’s common stock (or common stock equivalents in lieu t...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...